Oramed Pharmaceuticals (ORMP) Total Current Liabilities (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Total Current Liabilities came in at $10.6 million in Q1 2026, up 92.33% YoY from $5.5 million in Q1 2025, and down 44.66% on a QoQ basis from $19.1 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Total Current Liabilities (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 16 years of Total Current Liabilities data on file, last reported at $10.6 million in Q1 2026.
- Quarterly Total Current Liabilities rose 92.33% year-over-year to $10.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.6 million (up 92.33% YoY) and the FY2025 annual result came in at $19.1 million, up 235.73% from the prior year.
- Total Current Liabilities slipped to $10.6 million in Q1 2026, from $19.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $78.2 million in Q3 2023 to a low of $1.1 million in Q2 2023.
- A 5-year average of $15.0 million and a median of $6.1 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 1098.08% — and 2024, when it slumped 93.25%.
- Tracing ORMP's Total Current Liabilities over 5 years: stood at $5.7 million in 2022, then jumped by 826.11% to $53.2 million in 2023, then tumbled by 89.32% to $5.7 million in 2024, then surged by 235.73% to $19.1 million in 2025, then sank by 44.66% to $10.6 million in 2026.
- The last three Total Current Liabilities figures came in at $10.6 million (Q1 2026), $19.1 million (Q4 2025), and $6.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 10.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.73 Mn |
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 19.09 Mn |
| Sep 30, 2025 | 6.12 Mn |
| Jun 30, 2025 | 3.69 Mn |
| Mar 31, 2025 | 5.49 Mn |
| Dec 31, 2024 | 5.69 Mn |
| Sep 30, 2024 | 5.27 Mn |
| Jun 30, 2024 | 3.73 Mn |
| Mar 31, 2024 | 33.56 Mn |
| Dec 31, 2023 | 53.21 Mn |
| Sep 30, 2023 | 78.18 Mn |
| Jun 30, 2023 | 1.07 Mn |
| Mar 31, 2023 | 4.97 Mn |
| Dec 31, 2022 | 5.75 Mn |
| Sep 30, 2022 | 6.53 Mn |
| Jun 30, 2022 | 6.42 Mn |
| Mar 31, 2022 | 6.32 Mn |
| Nov 30, 2021 | 7.66 Mn |
| Aug 31, 2021 | 6.68 Mn |